|
|
Jaap Twisk, Donald L. Gillian-Daniel, Angie Tebon, Lin Wang, P. Hugh R. Barrett, Alan D. Attie
J Clin Invest. 2000;
105(4):521
doi:10.1172/JCI8623
Abstract |
Full text
| PDF
| Supplemental material

F
amilial hypercholesterolemia is caused by mutations in the LDL receptor gene (Ldlr). Elevated plasma LDL levels result from slower LDL catabolism and a paradoxical lipoprotein overproduction. We explored the relationship between the presence of the LDL receptor and lipoprotein secretion in hepatocytes from both wild-type and LDL receptor–deficient mice. Ldlr–/– hepatocytes secreted apoB100 at a 3.5-fold higher rate than did wild-type hepatocytes. ApoB mRNA abundance, initial apoB synthetic rate, and abundance of the microsomal triglyceride transfer protein 97-kDa subunit did not differ between wild-type and Ldlr–/– cells. Pulse-chase analysis and multicompartmental modeling revealed that in wild-type hepatocytes, approximately 55% of newly synthesized apoB100 was degraded. However, in Ldlr–/– cells, less than 20% of apoB was degraded. In wild-type hepatocytes, approximately equal amounts of LDL receptor–dependent apoB100 degradation occured via reuptake and presecretory mechanisms. Adenovirus-mediated overexpression of the LDL receptor in Ldlr–/– cells resulted in degradation of approximately 90% of newly synthesized apoB100. These studies show that the LDL receptor alters the proportion of apoB that escapes co- or post-translational presecretory degradation and mediates the reuptake of newly secreted apoB-containing lipoprotein particles.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
About CrossRef
| Title and authors |
Publication |
Year |
. |
Hypobetalipoproteinemia
Patrizia Tarugi, Maurizio Averna |
Advances in Clinical Chemistry Volume 54 |
2011 |
.
|
Genetic determinants of apolipoprotein B-100 kinetics
Theodore WK Ng, Esther MM Ooi, Gerald F Watts, Dick C Chan, P Hugh R Barrett |
Curr Opin Lipidol |
2010 |
.
|
Apolipoprotein B100 secretion by cultured ARPE-19 cells is modulated by alteration of cholesterol levels
Tinghuai Wu, Masashi Fujihara, Jane Tian, Miroslava Jovanovic, Celene Grayson, Marisol Cano, Peter Gehlbach, Philippe Margaron, James T. Handa |
J Neurochemistry |
2010 |
.
|
Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice
Seongah Han, Chien-Ping Liang, Marit Westerterp, Takafumi Senokuchi, Carrie L. Welch, Qizhi Wang, Michihiro Matsumoto, Domenico Accili, Alan R. Tall |
Journal Clinical Investigation |
2009 |
.
|
Parameter Estimation for Linear Compartmental Models—A Sensitivity Analysis Approach
Barbara Juillet, Cécile Bos, Claire Gaudichon, Daniel Tomé, Hélène Fouillet |
Ann Biomed Eng |
2009 |
.
|
Cellular cholesterol trafficking and compartmentalization
Elina Ikonen |
Nature Reviews Molecular and Cell Biology |
2008 |
.
|
Inhibition of microsomal triglyceride transfer protein expression and atherogenic risk factor apolipoprotein B100 secretion by tanshinone IIA in HepG2 cells
Yun-Jeong Kang, Un-Ho Jin, Hyen-Wook Chang, Jong-Keun Son, Seung Ho Lee, Kun-Ho Son, Young-Chae Chang, Young-Choon Lee, Cheorl-Ho Kim |
Phytother Res |
2008 |
.
|
The physiological and molecular regulation of lipoprotein assembly and secretion
Daniel A. Blasiole, Roger A. Davis, Alan D. Attie |
Mol Biosyst |
2007 |
.
|
Genetics of familial hypobetalipoproteinemia
Patrizia Tarugi, Maurizio Averna |
Future Lipidology |
2007 |
.
|
The proprotein convertases are potential targets in the treatment of dyslipidemia
Nabil G. Seidah, Annik Prat |
J Mol Med-JMM |
2007 |
.
|
Regulation of hepatic production of lipoproteins containing apolipoprotein B by ER-associated degradation
Louis R Lapierre, Roger S McLeod |
Future Lipidology |
2007 |
.
|
Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia
Christopher Jones, Rita Garuti, Peter Michaely, Wei-Ping Li, Nobuyo Maeda, Jonathan C. Cohen, Joachim Herz, Helen H. Hobbs |
Journal Clinical Investigation |
2007 |
.
|
The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR
Nasha Nassoury, Daniel A. Blasiole, Angie Tebon Oler, Suzanne Benjannet, Josée Hamelin, Vivianne Poupon, Peter S. McPherson, Alan D. Attie, Annik Prat, Nabil G. Seidah |
Traffic |
2007 |
.
|
Diabetic dyslipidaemia
Martin Adiels, Sven-Olof Olofsson, Marja-Riitta Taskinen, Jan Borén |
Curr Opin Lipidol |
2006 |
.
|
Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I
Jenelle M. Timmins, Ji-Young Lee, Elena Boudyguina, Kimberly D. Kluckman, Liam R. Brunham, Anny Mulya, Abraham K. Gebre, Jonathan M. Coutinho, Perry L. Colvin, Thomas L. Smith, Michael R. Hayden, Nobuyo Maeda, John S. Parks |
Journal Clinical Investigation |
2005 |
.
|
Monogenic Hypocholesterolaemic Lipid Disorders and Apolipoprotein B Metabolism
Amanda J. Hooper, Frank M. van Bockxmeer, John R. Burnett |
Critical Reviews in Clinical Laboratory Sciences |
2005 |
.
|
Oxidation, lipoproteins, and atherosclerosis: which is wrong, the antioxidants or the theory?
Kevin Jon Williams, Edward A Fisher |
Current Opinion in Clinical Nutrition and Metabolic Care |
2005 |
.
|
Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis
S.-O. OLOFSSON, J. BOREN |
j int med |
2005 |
.
|
Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production
Meihui Pan, Arthur I. Cederbaum, Yuan-Li Zhang, Henry N. Ginsberg, Kevin Jon Williams, Edward A. Fisher |
Journal Clinical Investigation |
2004 |
.
|
Kevin Williams, Edward Fisher |
Curr Opin Lipidol |
2001 |
.
|
|
|
|